Takeda and BIRAC Sign MoU to Foster Healthcare Innovation in India

Takeda and BIRAC Sign MoU to Foster Healthcare Innovation in India

VoM News Desk | December 5, 2023 | 11:05 AM IST | Breaking News | Follow on Google News

Takeda and BIRAC Sign MoU to Foster Healthcare Innovation in India

Takeda and BIRAC Sign MoU to Foster Healthcare Innovation in India

Takeda, a global biopharmaceutical company, has announced a three-year Memorandum of Understanding (MoU) with the Biotechnology Industry Research Assistance Council (BIRAC), a public sector enterprise established by the Department of Biotechnology, Government of India. This partnership aims to boost healthcare innovation by providing support to Indian entrepreneurs and innovators, from conceptualization to market deployment of new healthcare solutions.

Collaboration Aligns with BIRAC’s Vision

The collaboration aligns with BIRAC’s vision of enhancing strategic research and innovation in the Indian biotech industry, focusing on creating affordable products for the broader society. The announcement was made at the Global Bio-India (GBI) 2023 event, which is a major international congregation of biotechnology stakeholders.

Leadership Comments on the Partnership

Sanjay Patel, Global Head of Data Digital and Technology Innovation Capability Solutions at Takeda Pharmaceuticals International AG, highlighted India’s potential as a vibrant healthcare market. He emphasized the role of domestic healthcare startups in driving global advancements in healthcare. Serina Fischer, General Manager of Takeda Biopharmaceuticals India Pvt. Ltd., expressed commitment to discovering and delivering transformative treatments, aligning with the Indian Government’s aspirations for local healthcare solutions with a global impact.

Ruchi Sogarwal, Head of Corporate Affairs at Takeda Biopharmaceuticals India Pvt. Ltd., stressed the importance of collaboration between government, academia, and industry in accelerating innovation and building disruptive healthcare technology solutions.

Takeda’s Global Commitment and Forward-Looking Statements

Takeda is focused on creating better health for people worldwide, working in core therapeutic and business areas such as gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. The company aims to improve patient experiences and advance treatment options through a diverse pipeline. This MoU is part of Takeda’s commitment to patients, the planet, and innovation, as a values-based, R&D-driven biopharmaceutical leader.

The press release includes forward-looking statements based on various assumptions and factors about Takeda’s future business, position, and results of operations. These statements reflect Takeda’s current beliefs and expectations but are subject to risks and uncertainties that may cause actual results to differ materially.

This MoU signifies a critical step in enhancing healthcare innovation in India and globally, leveraging Takeda’s expertise and BIRAC’s strategic vision.

Takeda and BIRAC Sign MoU to Foster Healthcare Innovation in India: In case of rectification of any error in this Article, Visit on Correction Policy or Register your Query

VoM News Desk

VoM News is an online web portal in jammu Kashmir offers regional, National & global news.